Cargando…

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

PURPOSE: This study aimed to determine whether baseline blood inflammatory markers can predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). METHODS: The study included 158 patients with mRCC treated with first-line targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung Han, Park, Eun Young, Joo, Jungnam, Chung, Jinsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312581/
https://www.ncbi.nlm.nih.gov/pubmed/30662462
http://dx.doi.org/10.1155/2018/1953571
_version_ 1783383793659281408
author Kim, Sung Han
Park, Eun Young
Joo, Jungnam
Chung, Jinsoo
author_facet Kim, Sung Han
Park, Eun Young
Joo, Jungnam
Chung, Jinsoo
author_sort Kim, Sung Han
collection PubMed
description PURPOSE: This study aimed to determine whether baseline blood inflammatory markers can predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). METHODS: The study included 158 patients with mRCC treated with first-line targeted therapy between 2002 and 2016. A multivariable cox proportional hazards model identified inflammatory factors that predict PFS and OS. Using bootstrap method, new prognostic model compared with Heng and modified MSKCC risk model (mMSKCC). The effect of inflammatory factors were investigated by comparing increased C-index adding significant inflammatory factors to Heng and mMSKCC model. RESULTS: On multivariable analysis, nephrectomy (HR 0.48), NLR (HR 1.04), were significant risk factors for PFS; nephrectomy (HR 0.38), hemoglobin (HR 1.71), alkaline phosphatase (HR 1.73), NLR (HR 1.01) and DRR (HR 1.34), were significant factors for OS (p<0.05). Our new model that incorporated NLR and DRR had higher (though insignificant) predictability (C-index=0.610) than mMSKCC risk model (C-index=0.569) in PFS and significantly better predictability (C-index=0.727) than Heng and mMSKCC risk model (C-index, 0.661, 0.612, respectively) in OS. Adding inflammatory factors to the Heng criteria (C-index, 0.697 for OS) and MSKCC (0.691 for OS) tended to improve their predictive abilities. CONCLUSIONS: The NLR and DRR may increase predictive ability compared to the established Heng and mMSKCC risk models in mRCC.
format Online
Article
Text
id pubmed-6312581
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63125812019-01-20 The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma Kim, Sung Han Park, Eun Young Joo, Jungnam Chung, Jinsoo J Oncol Research Article PURPOSE: This study aimed to determine whether baseline blood inflammatory markers can predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). METHODS: The study included 158 patients with mRCC treated with first-line targeted therapy between 2002 and 2016. A multivariable cox proportional hazards model identified inflammatory factors that predict PFS and OS. Using bootstrap method, new prognostic model compared with Heng and modified MSKCC risk model (mMSKCC). The effect of inflammatory factors were investigated by comparing increased C-index adding significant inflammatory factors to Heng and mMSKCC model. RESULTS: On multivariable analysis, nephrectomy (HR 0.48), NLR (HR 1.04), were significant risk factors for PFS; nephrectomy (HR 0.38), hemoglobin (HR 1.71), alkaline phosphatase (HR 1.73), NLR (HR 1.01) and DRR (HR 1.34), were significant factors for OS (p<0.05). Our new model that incorporated NLR and DRR had higher (though insignificant) predictability (C-index=0.610) than mMSKCC risk model (C-index=0.569) in PFS and significantly better predictability (C-index=0.727) than Heng and mMSKCC risk model (C-index, 0.661, 0.612, respectively) in OS. Adding inflammatory factors to the Heng criteria (C-index, 0.697 for OS) and MSKCC (0.691 for OS) tended to improve their predictive abilities. CONCLUSIONS: The NLR and DRR may increase predictive ability compared to the established Heng and mMSKCC risk models in mRCC. Hindawi 2018-12-18 /pmc/articles/PMC6312581/ /pubmed/30662462 http://dx.doi.org/10.1155/2018/1953571 Text en Copyright © 2018 Sung Han Kim et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kim, Sung Han
Park, Eun Young
Joo, Jungnam
Chung, Jinsoo
The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title_full The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title_fullStr The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title_full_unstemmed The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title_short The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma
title_sort de ritis and neutrophil-to-lymphocyte ratios may aid in the risk assessment of patients with metastatic renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312581/
https://www.ncbi.nlm.nih.gov/pubmed/30662462
http://dx.doi.org/10.1155/2018/1953571
work_keys_str_mv AT kimsunghan thederitisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT parkeunyoung thederitisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT joojungnam thederitisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT chungjinsoo thederitisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT kimsunghan deritisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT parkeunyoung deritisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT joojungnam deritisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma
AT chungjinsoo deritisandneutrophiltolymphocyteratiosmayaidintheriskassessmentofpatientswithmetastaticrenalcellcarcinoma